Signifance of Serum CA153 in the Differential Diagnosis Between Benign and Malignant Lung Diseases

王赟,陈小东,张光明,邓守真,张静,张斯为

DOI: https://doi.org/10.3969/j.issn.1007-3639.2002.01.014

1998-01-01

Abstract:Purpose:To study the clinical significance of a tumor marker, serum CA153(sCA153), in the differential diagnosis between benign and malignant lung diseases, and in the evolution of lung cancer. Methods:124 serum samples was collected from 124 in-ward patients. Among them, 74 patients had lung cancer, and 50 patients had benign lung diseases (BLD). The concentrations of sCA153 and serum CEA (sCEA) were determined by immunoradiometric assay method.Results:In the lung cancer group, the total positive rate of sCA153 was 62.68%, which was evidently higher than that in BLD group(P0.001). In the lung cancer group, the positive rates of sCA153 in different patients with different cell-types of lung cancer were as follows: squamous cell carcinoma 50%, adeonocarcinoma 75%, small-cell lung cancer 50%. The sensitivity and specificity of sCA153 in diagnosing lung cancer were respectively ,62.68% and 88%. The sensitivity and specificity of sCEA were respectively 45.07% and 98%. The sensitivity of sCA153 was significantly higher then that of sCEA(P0.05), but there was no difference in the specificity between sCA153 and sCEA (P0.9). In the different cell types of lung cancer patients, the concentration of sCA153 in lung adenocarcinoma patients was increased much more than that of other lung cancer groups (P0.05). The concentration and the sensitivity of sCA153 were relative to the clinical stage of lung cancer and the more advanced the stage, the higher the level of sCA153 (P0.05), the positive rate of sCA153 was 50% in diagnosing early-stage lung cancers. Follow-up of the patients treated with chemotherapy showed that the concentration of sCA153 was inversely related to the results. Conclusions:CA153 has high clinical value in the diagnosis and prognosis of lung cancer, and can be regarded as a new tumor marker in detecting lung cancer, especially in adenocarcinoma, instead of CEA.